Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

[1]  D. Rakheja,et al.  IDH mutations in acute myeloid leukemia. , 2012, Human pathology.

[2]  M. Cazzola,et al.  The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms , 2011, Haematologica.

[3]  Catriona Jamieson,et al.  Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[5]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Ko,et al.  The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia , 2011, Leukemia.

[7]  V. Martinelli,et al.  Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. , 2010, Blood.

[8]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[9]  D. Gilliland,et al.  Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms , 2010, Leukemia.

[10]  A. Jankowska,et al.  UTX Mutations and Epigenetic Changes In MDS/MPN and Related Myeloid Malignancies , 2010 .

[11]  M. Odero,et al.  Frequent Mutation of the Polycomb-Associated Gene ASXL1 In Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia , 2010 .

[12]  A. Jankowska,et al.  Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2 , 2010 .

[13]  K. Bhalla,et al.  Synergistic Activity of Combinations of JAK2 Kinase Inhibitor with PI3K/mTOR, MEK or PIM Kinase Inhibitor Against Human Myeloproliferative Neoplasm Cells Expressing JAK2V617F , 2010 .

[14]  L. Bullinger,et al.  TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG) , 2010 .

[15]  P. Dubreuil,et al.  Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients , 2010 .

[16]  A. Tefferi,et al.  Circulating IL-2R, IL-8, IL-15 and CXCL10 Levels Are Independently Prognostic In Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study , 2010 .

[17]  T. Barbui,et al.  A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results , 2010 .

[18]  N. Socci,et al.  High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial , 2010 .

[19]  M. Cazzola,et al.  Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU) , 2010 .

[20]  A. Tefferi,et al.  A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms , 2010 .

[21]  T. Barbui,et al.  Survival and Risk of Leukemic transformation in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study on 1,104 Patients , 2010 .

[22]  T. Graubert,et al.  KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial , 2010 .

[23]  R. Mesa,et al.  A Phase-2 Trial of Low-Dose Pomalidomide In Myelofibrosis with Anemia , 2010 .

[24]  M. Caligiuri,et al.  Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study , 2010 .

[25]  M. McDevitt,et al.  Disruption of the ASXL1 Gene Is Prevalent In PMF: Analysis of Molecular Genetics and Clinical Phenotypes , 2010 .

[26]  O. Kilpivaara,et al.  High Rates of Molecular Response After Long-Term Follow-up of Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia Vera (PV) Treated with Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) , 2010 .

[27]  K. Döhner,et al.  Mutations of EZH2 In Myeloproliferative Neoplasms with Myelofibrosis: Correlation with Molecular and Clinical Data , 2010 .

[28]  B. Ko,et al.  Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations , 2010 .

[29]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[30]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[31]  G. Mufti,et al.  Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. , 2010, Blood.

[32]  E. Holme,et al.  IDH2 Mutations in Patients with d-2-Hydroxyglutaric Aciduria , 2010, Science.

[33]  A. Tefferi,et al.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.

[34]  R. Hills,et al.  The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. , 2010, Blood.

[35]  O. Bernard,et al.  Chromosomal abnormalities in transformed Ph‐negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations , 2010, Genes, chromosomes & cancer.

[36]  A. Jankowska,et al.  Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies , 2010, Leukemia.

[37]  D. Birnbaum,et al.  ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia , 2010, British journal of haematology.

[38]  A. Tefferi,et al.  IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia , 2010, Leukemia.

[39]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[40]  O. Abdel-Wahab,et al.  The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration , 2010, Leukemia.

[41]  Martin Dugas,et al.  Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Soulier,et al.  Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. , 2010, Blood.

[43]  Erin F. Simonds,et al.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.

[44]  H. Dombret,et al.  Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[46]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[48]  P. Campbell,et al.  The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. , 2010, Blood.

[49]  P. Guglielmelli,et al.  Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis , 2010, Leukemia.

[50]  Mondira Kundu,et al.  Lnk constrains myeloproliferative diseases in mice. , 2010, The Journal of clinical investigation.

[51]  A. Tefferi,et al.  IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms , 2010, Leukemia.

[52]  D. Gilliland,et al.  IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis , 2010, Leukemia.

[53]  M. Cazzola,et al.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms , 2010, Leukemia.

[54]  A. Tefferi,et al.  WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations , 2010, Leukemia.

[55]  A. Tefferi,et al.  Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q) , 2010, Leukemia.

[56]  A. Tefferi,et al.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.

[57]  R. Kusec,et al.  High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression , 2010, Leukemia.

[58]  R. Kusec,et al.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. , 2010, Blood.

[59]  D. Birnbaum,et al.  Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.

[60]  A. Tefferi,et al.  MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. , 2010, Leukemia.

[61]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[62]  A. Tichelli,et al.  Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. , 2010, Blood.

[63]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[64]  A. Kohlmann,et al.  Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis , 2010, Haematologica.

[65]  M. Cazzola,et al.  Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia , 2010, Leukemia.

[66]  D. Birnbaum,et al.  Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias , 2010, Leukemia.

[67]  J. Licht,et al.  Deregulation of H3K27 methylation in cancer , 2010, Nature Genetics.

[68]  A. Tefferi,et al.  Age and platelet count are IPSS‐independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival , 2010, European journal of haematology.

[69]  A. Green,et al.  Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. , 2010, The New England journal of medicine.

[70]  B. Johansson,et al.  The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. , 2010, Human molecular genetics.

[71]  O. Abdel-Wahab,et al.  Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.

[72]  J. Hess,et al.  Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. , 2010, Blood.

[73]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[74]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[75]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[76]  M. Griesshammer,et al.  Bone marrow fibrosis and diagnosis of essential thrombocythemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  A. Tefferi,et al.  Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosine , 2009, American journal of hematology.

[78]  P. Guglielmelli,et al.  The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms. , 2009 .

[79]  M. Konopleva,et al.  Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  S. Um,et al.  ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1* , 2009, The Journal of Biological Chemistry.

[81]  F. Passamonti,et al.  Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype , 2009, American journal of hematology.

[82]  A. Sharrocks.  Faculty Opinions recommendation of JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. , 2009 .

[83]  O. Abdel-Wahab,et al.  Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms , 2009, American journal of hematology.

[84]  D. Birnbaum,et al.  TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[85]  D. Linch,et al.  In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. , 2009, Blood.

[86]  R. Levine,et al.  A progenitor cell origin of myeloid malignancies , 2009, Proceedings of the National Academy of Sciences.

[87]  Andrew J. Bannister,et al.  JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin , 2009, Nature.

[88]  H. Deeg,et al.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Thiele,et al.  Prodromal myeloproliferative neoplasms: The 2008 WHO classification , 2009, American journal of hematology.

[90]  T. Barbui,et al.  Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. , 2009, Blood.

[91]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[92]  D. Birnbaum,et al.  Mutations of ASXL1 gene in myeloproliferative neoplasms , 2009, Leukemia.

[93]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[94]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[95]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[96]  D. Steensma,et al.  Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not , 2009, American journal of hematology.

[97]  G. Neri,et al.  Faculty Opinions recommendation of Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. , 2009 .

[98]  D. Gilliland,et al.  Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.

[99]  D. Gilliland,et al.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.

[100]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[101]  A. Hall,et al.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.

[102]  S. Chevret,et al.  Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.

[103]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[104]  M. Björkholm,et al.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. , 2008, Blood.

[105]  W. Vainchenker,et al.  The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. , 2008, Blood.

[106]  P. Guglielmelli,et al.  Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal , 2008, Leukemia.

[107]  R. Mesa,et al.  Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.

[108]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[109]  I. Issaeva,et al.  UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development , 2007, Nature.

[110]  A. Tefferi,et al.  Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes , 2007, Leukemia.

[111]  D. Gilliland,et al.  Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes , 2007, Stem cells.

[112]  A. Tefferi,et al.  Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation , 2007, British journal of haematology.

[113]  A. Berrebi,et al.  Busulphan is safe and efficient treatment in elderly patients with essential thrombocythemia , 2007, Leukemia.

[114]  A. Tefferi,et al.  Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients , 2007, Leukemia.

[115]  M. Stratton,et al.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.

[116]  D. Gilliland,et al.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. , 2006, Blood.

[117]  J. Vardiman,et al.  Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. , 2006, Best practice & research. Clinical haematology.

[118]  Sandra A. Moore,et al.  MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.

[119]  S. Um,et al.  Additional Sex Comb-like 1 (ASXL1), in Cooperation with SRC-1, Acts as a Ligand-dependent Coactivator for Retinoic Acid Receptor* , 2006, Journal of Biological Chemistry.

[120]  E. Thiel,et al.  Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia , 2005, Annals of Hematology.

[121]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[122]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[123]  T. Barbui,et al.  Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. , 2005 .

[124]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[125]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[126]  M. Cazzola,et al.  Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman , 2004, Annals of Hematology.

[127]  H. Kluin-Nelemans,et al.  Cladribine therapy for systemic mastocytosis. , 2003, Blood.

[128]  F. Mandelli,et al.  Long‐term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution , 2003, British journal of haematology.

[129]  A. Tefferi,et al.  Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. , 2003, Blood.

[130]  R. Latagliata,et al.  Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971–1991) , 1998, Leukemia.

[131]  G. Ahmann,et al.  Fluorescent in situ hybridization studies of lymphocytes and neutrophils in chronic granulocytic leukemia. , 1995, Cancer genetics and cytogenetics.

[132]  H. Drexler,et al.  Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. , 1988, Leukemia.

[133]  T. Pearson,et al.  Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre , 1985, British journal of haematology.

[134]  J. Adamson,et al.  Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia. , 1985, The Journal of clinical investigation.

[135]  K. Sikora,et al.  Leukemia , 1984, British Journal of Cancer.

[136]  Rotterdam,et al.  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). , 1981, British journal of cancer.

[137]  V. Najfeld,et al.  Involvement of the B-lymphoid system in chronic myelogenous leukaemia , 1980, Nature.

[138]  J. Adamson,et al.  Polycythemia vera: stem-cell and probable clonal origin of the disease. , 1976, The New England journal of medicine.

[139]  S. Gartler,et al.  Clonal origin of chronic myelocytic leukemia in man. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[140]  N. Komatsu.  [Myeloproliferative neoplasms]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[141]  Ryan D. Morin,et al.  Somatic mutations at EZH 2 Y 641 act dominantly through a mechanism of selectively altered PRC 2 catalytic activity , to increase H 3 K 27 trimethylation , 2011 .

[142]  R. Mesa,et al.  A phase-2 trial of low-dose pomalidomide in myelofibrosis , 2011, Leukemia.

[143]  A. Tefferi,et al.  The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status—clinical correlates in a study of 226 consecutive patients , 2010, Leukemia.

[144]  A. Tefferi,et al.  JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival , 2010, Leukemia.

[145]  O. Bernard,et al.  Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias , 2010, Leukemia.

[146]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[147]  D. Gilliland,et al.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.

[148]  A. Tefferi.  The history of myeloproliferative disorders: before and after Dameshek , 2008, Leukemia.

[149]  A. Tefferi,et al.  Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[150]  A. Aventín,et al.  Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. , 2000, Haematologica.

[151]  G. Faguet,et al.  Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. , 1981, Blood.

[152]  P. Fialkow,et al.  Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. , 1978, Blood.

[153]  Landaw Sa.  Acute leukemia in polycythemia vera. , 1976, Seminars in hematology.